Accenture Accepting Emerging Innovators and Distributors for HealthTech Innovation Challenge
Accenture announced it is accepting applications for the third annual Accenture HealthTech Innovation Challenge (#HealthTechChallenge on twitter), which aims to improve the way people access and manage healthcare. It brings together startups with health and life sciences companies to tackle some of the world’s greatest health challenges, including access, quality, and affordability-of-care options.
The three categories for the third annual Accenture HealthTech Innovation Challenge are:
- Keeping a population healthy through wellness and prevention. This category focuses on minimizing hospital visits; wellness/lifestyle management; remote care delivery models; social determinates of health; and better education.
- Using digital health solutions to deliver better patient outcomes. This category focuses on delivering the best outcomes by leveraging digital health solutions, including telehealth; artificial intelligence; digital clinical trials; blockchain; internet of things; drones; digital pills; 3D printing; and real-world evidence.
- Improving healthcare delivery for the patient. This category focuses on healthcare services and efficient healthcare through office/patient management; cost transparency/payments; strategic sourcing; health records; care coordination; and enterprise workflow.
Key criteria that applications should address include solution innovation, solution design quality, disruptive business model, potential impact on patient outcomes, and solution scalability.
Emerging healthcare technology innovators and disruptors are encouraged to apply for the program by clicking here now through Sept. 1.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
